Disease · MONDO_0100233
Targets46
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 46
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| HTR2A | 5-hydroxytryptamine receptor 2A | 2 | Serotonin 2a (5-HT2a) receptor antagonist | Phase 2 | https://conductscience.org/library/genes/3356 | Drugs and targets |
| HTR2C | 5-hydroxytryptamine receptor 2C | 2 | Serotonin 2c (5-HT2c) receptor antagonist | Phase 2 | https://conductscience.org/library/genes/3358 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 2 | Glucocorticoid receptor agonist | Unknown | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PDE10A | 3',5'-cyclic phosphodiesterase | 2 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 10A inhibitor | Phase 2/3 | https://conductscience.org/library/genes/10846 | Drugs and targets |
| PDE3A | 3',5'-cyclic phosphodiesterase | 2 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 3A inhibitor | Phase 2/3 | https://conductscience.org/library/genes/5139 | Drugs and targets |
| PDE4A | 3',5'-cyclic phosphodiesterase | 2 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/5141 | Drugs and targets |
| PDE4B | 3',5'-cyclic phosphodiesterase | 2 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/5142 | Drugs and targets |
| PDE4C | 3',5'-cyclic phosphodiesterase | 2 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/5143 | Drugs and targets |
| PDE4D | 3',5'-cyclic phosphodiesterase | 2 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/5144 | Drugs and targets |
| PDE5A | 3',5'-cyclic phosphodiesterase | 2 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 5A inhibitor | Phase 2/3 | https://conductscience.org/library/genes/8654 | Drugs and targets |
| ADORA2A | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/136 | Drugs and targets |
| ADRB2 | Beta-2 adrenergic receptor | 1 | Beta-2 adrenergic receptor agonist | Unknown | https://conductscience.org/library/genes/154 | Drugs and targets |
| CCR5 | C-C chemokine receptor type 5 | 1 | C-C chemokine receptor type 5 antagonist | Phase 2/3 | https://conductscience.org/library/genes/1234 | Drugs and targets |
| CHRNA3 | Neuronal acetylcholine receptor; alpha3/beta4 | 1 | Neuronal acetylcholine receptor; alpha3/beta4 partial agonist | Phase 2 | https://conductscience.org/library/genes/1136 | Drugs and targets |
| CHRNB4 | Neuronal acetylcholine receptor; alpha3/beta4 | 1 | Neuronal acetylcholine receptor; alpha3/beta4 partial agonist | Phase 2 | https://conductscience.org/library/genes/1143 | Drugs and targets |
| CNR1 | Cannabinoid receptor 1 | 1 | Cannabinoid CB1 receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/1268 | Drugs and targets |
| CYP3A4 | Cytochrome P450 3A | 1 | Cytochrome P450 3A inhibitor | Phase 2 | https://conductscience.org/library/genes/1576 | Drugs and targets |
| CYP3A43 | Cytochrome P450 3A | 1 | Cytochrome P450 3A inhibitor | Phase 2 | https://conductscience.org/library/genes/64816 | Drugs and targets |
| CYP3A5 | Cytochrome P450 3A | 1 | Cytochrome P450 3A inhibitor | Phase 2 | https://conductscience.org/library/genes/1577 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100233/targets